CG
XERS icon

Cutler Group’s Xeris Biopharma Holdings XERS Stock Holding History

Cutler Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-700
Closed -$1K – 3806
2023
Q4 		$1K Hold
700
– – ﹤0.01% 3505
2023
Q3 		$1K Hold
700
– – ﹤0.01% 3681
2023
Q2 		$1K Hold
700
– – ﹤0.01% 3454
2023
Q1 		$1K Hold
700
– – ﹤0.01% 3611
2022
Q4 		$0 Hold
700
– – ﹤0.01% 5351
2022
Q3 		$1K Hold
700
– – ﹤0.01% 4741
2022
Q2 		$1K Sell
700
-3,044
-81% -$6.42K ﹤0.01% 4778
2022
Q1 		$9K Buy
+3,744
New +$9.15K ﹤0.01% 3725
2021
Q4 		– Sell
-1,700
Closed -$4K – 6206
2021
Q3 		$4K Buy
1,700
+600
+55% +$1.74K ﹤0.01% 4693
2021
Q2 		$4K Sell
1,100
-800
-42% -$3.05K ﹤0.01% 4662
2021
Q1 		$8K Buy
1,900
+1,600
+533% +$8.63K ﹤0.01% 4035
2020
Q4 		$1K Sell
300
-600
-67% -$3K ﹤0.01% 4622
2020
Q3 		$5K Buy
+900
New +$3.6K ﹤0.01% 3554

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Cutler Group's XERS Position: Q1 2024 in Review

Cutler Group sold out of Xeris Biopharma Holdings (XERS) in Q1 2024, closing a stake of 700 shares — an estimated $1K sold.

Cutler Group first reported a position in XERS in Q3 2020 and held it in 13 quarters. The position peaked at $9K in Q1 2022. 143 funds tracked by Wall St. Rank hold XERS as of Q1 2024.

  • Cutler Group reported no remaining Xeris Biopharma Holdings position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 700 Xeris Biopharma Holdings shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in Xeris Biopharma Holdings in Q3 2020 and held it in 13 quarters.
  • Cutler Group's Xeris Biopharma Holdings position peaked at $9K in Q1 2022.
  • 143 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.